akampion News

Please click here to subscribe to regular news updates from the akampioneer.com
Wednesday, December 7, 2016

Company News: ISA Pharmaceuticals Advances Personalized Cancer Treatment

Next-generation immunotherapy called MyISA® for individual cancer patients

ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has joined the recently established Tumor neoantigEn SeLection Alliance (TESLA), a global cancer neoantigen alliance forged by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute, which was announced on December 1st, 2016. Consisting of 30 of the world’s leading research organizations and corporations, the group’s focus will be on developing better predictive models for identifying neoantigens. The initiative will support tests carried out by its members and the consistent improvement of algorithms to analyze tumor DNA and RNA sequences in order to predict the immunogenic capacity of neoantigens.

This initiative will support ISA’s strategy to expand its innovative portfolio of cancer immunotherapies by developing personalized therapeutic SLP® vaccines directed against neoantigens under the MyISA® program.

Friday, November 18, 2016

Company News: Curetis Publishes Business and Financial Update for the First Nine Months 2016

- U.S. FDA trial completed with excellent top-line data

- Leading position in genetic antimicrobial resistance biomarker testing strengthened by GEAR acquisition

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today published a business and financial update for the first nine months ended September 30, 2016 and provided an outlook to coming months.

Recent Operational and Business Highlights

Unyvero US FDA Trial